Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.

Hébert V, Petit M, Maho-Vaillant M, Golinski ML, Riou G, Derambure C, Boyer O, Joly P, Calbo S.

Front Immunol. 2019 Aug 7;10:1794. doi: 10.3389/fimmu.2019.01794. eCollection 2019.

2.

Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation.

Becquet L, Abad C, Leclercq M, Miel C, Jean L, Riou G, Couvineau A, Boyer O, Tan YV.

J Neuroinflammation. 2019 Mar 20;16(1):64. doi: 10.1186/s12974-019-1447-y.

3.

Long-Term Increase of Kcnn4 Potassium Channel Surface Expression on B Cells in Pemphigus Patients after Rituximab Treatment.

Caillot F, Derambure C, Berkani N, Riou G, Maho-Vaillant M, Calbo S, Joly P, Musette P.

J Invest Dermatol. 2018 Dec;138(12):2666-2668. doi: 10.1016/j.jid.2018.05.034. Epub 2018 Jul 2. No abstract available.

4.

[Occupational therapy: benefit of early intervention in the manic phase].

Riou G.

Soins Psychiatr. 2017 Sep - Oct;38(312):35-40. doi: 10.1016/j.spsy.2017.06.011. Review. French.

PMID:
28886836
5.

Neuron-to-Neuron Transfer of FUS in Drosophila Primary Neuronal Culture Is Enhanced by ALS-Associated Mutations.

Feuillette S, Delarue M, Riou G, Gaffuri AL, Wu J, Lenkei Z, Boyer O, Frébourg T, Campion D, Lecourtois M.

J Mol Neurosci. 2017 May;62(1):114-122. doi: 10.1007/s12031-017-0908-y. Epub 2017 Apr 20.

PMID:
28429234
6.

A role for intestinal TLR4-driven inflammatory response during activity-based anorexia.

Belmonte L, Achamrah N, Nobis S, Guérin C, Riou G, Bôle-Feysot C, Boyer O, Richard V, Rego JC, Déchelotte P, Goichon A, Coëffier M.

Sci Rep. 2016 Oct 25;6:35813. doi: 10.1038/srep35813.

7.

Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.

Hardet R, Chevalier B, Dupaty L, Naïmi Y, Riou G, Drouot L, Jean L, Salvetti A, Boyer O, Adriouch S.

Mol Ther. 2016 Feb;24(1):87-95. doi: 10.1038/mt.2015.146. Epub 2015 Aug 12.

8.

Mutation and abnormal expression of the p53 gene in the viral skin carcinogenesis of epidermodysplasia verruciformis.

Padlewska K, Ramoz N, Cassonnet P, Riou G, Barrois M, Majewski S, Croissant O, Jablonska S, Orth G.

J Invest Dermatol. 2001 Oct;117(4):935-42.

9.

c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.

Riou G, Mathieu MC, Barrois M, Le Bihan ML, Ahomadegbe JC, Bénard J, Lê MG.

Int J Cancer. 2001 Jul 20;95(4):266-70.

10.

Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers.

Ahomadegbe JC, Tourpin S, Kaghad M, Zelek L, Vayssade M, Mathieu MC, Rochard F, Spielmann M, Tursz T, Caput D, Riou G, Bénard J.

Oncogene. 2000 Nov 9;19(47):5413-8.

11.
13.

Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.

Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou G, Bénard J.

Int J Cancer. 1996 Sep 27;68(1):67-74.

14.

Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children.

Vassal G, Terrier-Lacombe MJ, Lellouch-Tubiana A, Valery CA, Sainte-Rose C, Morizet J, Ardouin P, Riou G, Kalifa C, Gouyette A.

Int J Cancer. 1996 Apr 22;69(2):146-51.

15.

[High incidence of p53 mutations in primary and metastatic head and neck tumors. Frequent protein overexpression in normal epithelium].

Fogel S, Ahomadegbe JC, Barrois M, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G.

Bull Cancer. 1996 Mar;83(3):227-33. French.

PMID:
8695925
16.
17.

p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies.

Moll UM, Ostermeyer AG, Ahomadegbe JC, Mathieu MC, Riou G.

Hum Pathol. 1995 Dec;26(12):1293-301.

PMID:
8522300
18.

Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.

Moll UM, LaQuaglia M, Bénard J, Riou G.

Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407-11.

19.

c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis.

Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, Rochard F, Bernaudin JF, Riou G.

Int J Cancer. 1995 Apr 21;64(2):146-51.

PMID:
7615357
21.

Characterization of a new p53-mutated and hpv-negative human squamous-cell cervical carcinoma-derived cell-line.

Fogel S, Ahomadegbe J, Lebihan M, Barrois M, Riou G.

Int J Oncol. 1995 Mar;6(3):681-6.

PMID:
21556589
22.

The p53 and mdm-2 genes in human testicular germ-cell tumors.

Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ.

Mol Carcinog. 1995 Mar;12(3):124-31.

PMID:
7893365
23.

Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type.

Prost S, Lê MG, Douc-Rasy S, Ahomadegbe JC, Spielmann M, Guérin M, Riou G.

Int J Cancer. 1994 Sep 15;58(6):763-8.

PMID:
7927865
25.
26.

Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis.

Bénard J, Bourhis J, de Vathaire F, Ferrandis E, Terrier-Lacombe MJ, Lemerle J, Riou G, Hartmann O.

Prog Clin Biol Res. 1994;385:111-6.

PMID:
7972202
27.
28.

Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma.

Riou G, Lê MG, Travagli JP, Levine AJ, Moll UM.

J Natl Cancer Inst. 1993 Nov 3;85(21):1765-7. No abstract available.

PMID:
8411261
29.

Expression of the human fetal bac h19 gene in invasive cancers.

Doucrasy S, Coll J, Barrois M, Joubel A, Prost S, Dozier C, Stehelin D, Riou G.

Int J Oncol. 1993 May;2(5):753-8.

PMID:
21573620
30.

Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation.

Madelaine I, Prost S, Naudin A, Riou G, Lavelle F, Riou JF.

Biochem Pharmacol. 1993 Jan 26;45(2):339-48.

PMID:
8382060
31.

Human papillomavirus-negative status and c-myc gene overexpression: independent prognostic indicators of distant metastasis for early-stage invasive cervical cancers.

Riou G, Lê MG, Favre M, Jeannel D, Bourhis J, Orth G.

J Natl Cancer Inst. 1992 Oct 7;84(19):1525-6. No abstract available.

PMID:
1331478
32.

Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.

Moll UM, Riou G, Levine AJ.

Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7262-6.

33.

N-myc genomic content and DNA ploidy in stage IVS neuroblastoma.

Bourhis J, Dominici C, McDowell H, Raschella G, Wilson G, Castello MA, Plouvier E, Lemerle J, Riou G, Bénard J, et al.

J Clin Oncol. 1991 Aug;9(8):1371-5.

PMID:
2072140
34.
36.

Expression of MDR1 and GST pi genes in 35 advanced neuroblastomas.

Bourhis J, Hartmann O, DeVathaire F, Terrier-Lacombe MJ, Boccon-Gibod L, Lemerle J, Riou G, Bénard J.

Prog Clin Biol Res. 1991;366:127-34. No abstract available.

PMID:
2068133
37.

Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.

Bourhis J, Bénard J, DeVathaire F, Wilson GD, Hartmann O, Terrier-Lacombe MJ, Boccon-Gibod L, Lemerle J, Riou G.

Prog Clin Biol Res. 1991;366:107-13. No abstract available.

PMID:
2068130
38.

[Activation of N-myc oncogene and associated genes to chemoresistance, prognostic value for neuroblastoma].

Bénard J, Bourhis J, Riou G.

Bull Cancer. 1991 Jan;78(1):91-7. French.

PMID:
2021689
39.

Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.

Bourhis J, De Vathaire F, Wilson GD, Hartmann O, Terrier-Lacombe MJ, Boccon-Gibod L, McNally NJ, Lemerle J, Riou G, Bénard J.

Cancer Res. 1991 Jan 1;51(1):33-6.

40.

Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix.

Bourhis J, Le MG, Barrois M, Gerbaulet A, Jeannel D, Duvillard P, Le Doussal V, Chassagne D, Riou G.

J Clin Oncol. 1990 Nov;8(11):1789-96.

PMID:
2230867
41.

Expression of multidrug-resistance (MDR1) gene in normal epithelia and in invasive carcinomas of the uterine cervix.

Riou GF, Zhou D, Ahomadegbe JC, Gabillot M, Duvillard P, Lhomme C.

J Natl Cancer Inst. 1990 Sep 19;82(18):1493-6. Erratum in: J Natl Cancer Inst 1990 Nov 7;82(21):1724.

PMID:
1697346
42.
43.

Clinical significance of multiple drug resistance in human cancers.

Bénard J, Bourhis J, Riou G.

Anticancer Res. 1990 Sep-Oct;10(5A):1297-302. Review.

PMID:
1978633
44.
45.

Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA.

Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G.

Lancet. 1990 May 19;335(8699):1171-4.

PMID:
1971033
46.
47.

[Molecular genetics of uterine cervical cancer: application to prognosis].

Riou G.

Rev Prat. 1990 Jan 21;40(3):239-41. French. No abstract available.

PMID:
2406878
48.

[c-myc and c-Ha-ras proto-oncogenes in cervical cancer: prognostic value].

Riou G, Sheng ZM, Zhou D, Lusinchi A, Le Doussal V, Barrois M.

Bull Cancer. 1990;77(4):341-7. French.

PMID:
2191730
49.

Strong association between c-myb and oestrogen-receptor expression in human breast cancer.

Guérin M, Sheng ZM, Andrieu N, Riou G.

Oncogene. 1990 Jan;5(1):131-5.

PMID:
2181374
50.

[Expression of P-glycoprotein 170 (GP 170) and drug resistance in human cancers].

Bourhis J, Riou G, Bénard J.

Bull Cancer. 1990;77(10):957-65. Review. French.

PMID:
1979014

Supplemental Content

Support Center